Retatrutide: The Triple Agonist Redefining Obesity Therapy
Retatrutide: Mechanism of action, current clinical data & dosing of the first GIP/GLP-1/glucagon triple agonist. Evidence-based analysis by Jade Peptides.
Disclaimer: The peptides described in this article are intended exclusively for research purposes and are not approved for human consumption. This article does not replace medical advice.
Introduction
Retatrutide is one of those molecules that can only be properly understood when you grasp how the interplay of three metabolic signaling pathways – GIP, GLP-1 and glucagon – fundamentally controls the body's energy balance. As the first triple hormone receptor agonist of its class, retatrutide has achieved weight reductions in clinical trials that were previously only possible through bariatric surgery – with a single weekly injection.
Numerous exaggerated claims about retatrutide now circulate online – from unrealistic promises to oversimplified comparisons with semaglutide or tirzepatide. What is often missing: a differentiated assessment of the actual study data, the specific mechanisms of action, and the clinically relevant differences from existing incretin therapies. Retatrutide is not "a better semaglutide" – it solves a different problem in a fundamentally different way.
In this article you will learn:
- What retatrutide is and how it differs structurally from other peptides
- How the triple mechanism of action via GIP, GLP-1 and glucagon receptors works
- What Phase 2 and initial Phase 3 study results actually show
- Which dosing protocols are used in research
- Which side effects and safety signals are known
- How retatrutide compares to semaglutide and tirzepatide
What is Retatrutide?
Retatrutide (development code: LY3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly. It is the world's first unimolecular triagonist – a single molecule that simultaneously activates three G-protein-coupled receptors:
- GIP receptor (Glucose-dependent insulinotropic polypeptide)
- GLP-1 receptor (Glucagon-like Peptide-1)
- Glucagon receptor (GCG-R)
Think of retatrutide as a triple switch: While semaglutide flips only one switch (GLP-1) and tirzepatide operates two switches (GLP-1 + GIP), retatrutide activates all three simultaneously – each with different intensity.
Structurally, retatrutide is built on a GIP peptide backbone, not a GLP-1 backbone like semaglutide. Three non-coded amino acid residues at positions 2, 13 and 20 give the molecule special properties:
- Aib² (α-aminoisobutyric acid): Protects against degradation by DPP-4 (dipeptidyl peptidase-4)
- αMeL¹³ (α-methyl-L-leucine): Optimizes GIP activity and pharmacokinetics
- Aib²⁰: Improves the molecule's developability
A fatty diacid moiety extends the half-life to approximately 6 days, enabling once-weekly subcutaneous administration. Hepatic metabolism occurs without interaction with cytochrome P450 enzymes.
Mechanism of Action
GIP Receptor Agonism – The Dominant Signaling Pathway
Compared to endogenous ligands, retatrutide is 8.9-fold more potent at the GIP receptor than native GIP (EC₅₀: 0.0643 nM). This is by design: the molecule was built on a GIP backbone.
GIP receptor activation causes:
- Glucose-dependent insulin secretion – Insulin is released only when blood glucose is elevated, minimizing hypoglycemia risk
- Improved lipid metabolism – Accelerated lipid clearance and reduced fat deposition
- Appetite modulation – Central GIP signals in the brain dampen appetite
- Improved insulin sensitivity – Support of postprandial glucose regulation
GLP-1 Receptor Agonism – Appetite Suppression and Glycemic Control
At the GLP-1 receptor, retatrutide is 2.5-fold less potent than native GLP-1 (EC₅₀: 0.775 nM). This means: the classic appetite suppression known from semaglutide is less pronounced with retatrutide.
GLP-1 receptor activation causes:
- Delayed gastric emptying – Meals are satiating for longer
- Central appetite suppression – Signals to hypothalamic satiety centers
- Enhanced glucose-dependent insulin secretion
- Suppression of glucagon release during hyperglycemia
- Postprandial blood glucose regulation
Glucagon Receptor Agonism – The Crucial Difference
Glucagon receptor activation is what fundamentally distinguishes retatrutide from all existing incretin therapies. At the glucagon receptor, retatrutide is less potent than native glucagon (EC₅₀: 5.79 nM), but even this moderate activation has profound metabolic effects.
Glucagon receptor activation causes:
- Increased energy expenditure – Stimulation of thermogenesis, particularly via hepatic pathways
- Enhanced lipolysis – Mobilization of stored fat as an energy source
- Increased hepatic fatty acid oxidation – explains the dramatic liver fat reduction
- Reduction of lipogenesis – Less de novo fat synthesis
- Modulation of hepatic glucose production (gluconeogenesis and glycogenolysis)
In preclinical models, glucagon receptor activity was responsible for 30–35% of observed weight loss – primarily through increased energy expenditure, not reduced food intake.
The Interplay – Synergy Rather Than Addition
The three receptors do not simply work additively, but synergistically:
| Receptor | Primary Effect | Retatrutide Potency vs. Native |
|---|---|---|
| GIP-R | Insulin sensitivity, lipid metabolism, appetite modulation | 8.9× more potent |
| GLP-1-R | Appetite suppression, gastric emptying, insulin secretion | 0.4× (attenuated) |
| GCG-R | Energy expenditure, fat mobilization, thermogenesis | 0.3× (attenuated) |
This balance is intentional: Strong GIP activation improves insulin sensitivity and lipid metabolism, moderate GLP-1 activation provides appetite reduction without extreme nausea, and moderate glucagon activation drives energy expenditure.
Clinical Data
Phase 1b Study – Type 2 Diabetes (Urva et al., 2022)
Study type: Phase 1b, multicenter, double-blind, placebo-controlled, randomized
Population: 72 participants with diagnosed type 2 diabetes
Results after 12 weeks:
- Placebo-adjusted weight reduction of 8.96 kg (approx. 10%) in the highest dose group (12 mg)
- Significant HbA1c reduction of −1.2%
- Improvement in lipid profile: reduction in LDL cholesterol, VLDL cholesterol, and triglycerides
- Good tolerability, no severe hypoglycemia
Source: Urva S et al. Lancet. 2022;400:1869–1881.
Phase 2 Obesity Study – The NEJM Study (Jastreboff et al., 2023)
Study type: Phase 2, multicenter, double-blind, randomized, placebo-controlled
Population: 338 adults with obesity (BMI ≥30) or overweight (BMI 27–30) with at least one weight-related comorbidity, without type 2 diabetes
Design: 48 weeks of treatment with weekly subcutaneous injection. Dose groups: 1 mg, 4 mg, 8 mg, 12 mg or placebo.
Results after 48 weeks (12 mg dose group):
- Mean weight reduction: −24.2% (Placebo: −2.1%)
- After 24 weeks already −17.5% weight loss
- Over 90% of participants lost ≥10% of their body weight
- 72% of participants with prediabetes normalized their glucose tolerance
- LDL cholesterol reduction of approximately 20%
Source: Jastreboff AM et al. N Engl J Med. 2023;389:514–526.
Phase 2 Study Type 2 Diabetes (Rosenstock et al., 2023)
Study type: Phase 2, double-blind, placebo- and active-controlled (dulaglutide 1.5 mg)
Results after 36 weeks (12 mg dose group):
| Endpoint | Result |
|---|---|
| HbA1c reduction | −2.02% (vs. −1.41% dulaglutide, vs. −0.01% placebo) |
| Weight loss | up to 16.9% |
| HbA1c ≤6.5% achieved | 77–82% of participants |
Source: Rosenstock J et al. Lancet. 2023;402:529–544.
MASLD Substudy – Liver Fat Reduction (Sanyal et al., 2024)
Population: 98 participants with MASLD and ≥10% liver fat
| Dose | Liver Fat Reduction (48 wk) | Steatosis Resolution (<5%, 48 wk) |
|---|---|---|
| 1 mg | −51.3% | 50% |
| 4 mg | −59.0% | 53% |
| 8 mg | −81.7% | 89% |
| 12 mg | −86.0% | 93% |
| Placebo | +4.6% | 0% |
All doses vs. placebo: p < 0.001
Source: Sanyal AJ et al. Nat Med. 2024;30(7):2037–2048.
Phase 3 Study TRIUMPH-4 – First Phase 3 Results (December 2025)
Population: 445 adults with obesity or overweight and knee osteoarthritis
| Endpoint | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Weight reduction | −26.4% | −28.7% (−32.3 kg) | −2.1% |
| WOMAC Pain | −4.5 points | −4.4 points | −2.4 points |
| Systolic blood pressure | – | −14.0 mmHg | – |
Over 12% of treated patients were completely pain-free after 68 weeks (vs. 4.2% placebo).
New safety signal – Dysesthesia:
| Dose | Frequency |
|---|---|
| 9 mg | 8.8% |
| 12 mg | 20.9% |
| Placebo | 0.7% |
Source: Eli Lilly Press Release, December 11, 2025.
Administration & Dosing
Note: This information comes exclusively from the research literature and is intended for research purposes. It does not constitute medical advice.
Administration
- Route: Subcutaneous (under the skin)
- Frequency: Once weekly
- Injection sites: Thigh, abdomen, or upper arm (rotation recommended)
- Half-life: Approximately 6 days
Dosing Protocol from Research
| Week | Dose (Target 12 mg) | Dose (Target 8 mg) |
|---|---|---|
| 1–4 | 2 mg/week | 2 mg/week |
| 5–8 | 4 mg/week | 4 mg/week |
| 9–12 | 6 mg/week | 8 mg/week (maintenance) |
| 13–16 | 9 mg/week | – |
| 17+ | 12 mg/week (maintenance) | – |
Key aspects:
- The starting dose of 2 mg was identified in Phase 2 as better tolerated than starting with 4 mg
- Dose escalation occurs every 4 weeks
- In case of significant nausea, escalation may be delayed
- The maximum research dose is 12 mg/week
Reconstitution (Research Context)
- Lyophilized peptide, storage at −20 °C
- Reconstitution with bacteriostatic water
- After reconstitution: storage at 2–8 °C, use within 2–4 weeks
- Do not shake – gently roll
Side Effects & Safety
Common Side Effects (dose-dependent)
| Side Effect | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Nausea | 38.1% | 43.2% | 10.7% |
| Diarrhea | 34.7% | 33.1% | 13.4% |
| Constipation | 21.8% | 25.0% | 8.7% |
| Vomiting | 20.4% | 20.9% | – |
What Was Not Observed
- No severe hypoglycemia in any study
- No medullary thyroid carcinoma or C-cell hyperplasia
- No hepatotoxicity signals, even in patients with MASLD
- No ketoacidosis, despite elevated β-hydroxybutyrate
Contraindications (based on study populations)
- Individuals with type 1 diabetes
- Pregnant or breastfeeding women
- Individuals with history of pancreatitis
- Individuals with family history of medullary thyroid carcinoma or MEN-2 syndrome
Who is Retatrutide Relevant For?
Potentially relevant for:
- Individuals with severe obesity (BMI ≥30)
- Individuals with obesity and type 2 diabetes
- Individuals with metabolic dysfunction-associated steatotic liver disease (MASLD/MASH)
- Individuals with obesity and knee osteoarthritis
- Cardiovascular and renal outcome studies (ongoing)
Currently not suitable / insufficiently studied for:
- Individuals with normal weight
- Individuals with type 1 diabetes
- Pregnant or breastfeeding women
- Children and adolescents
- Individuals with advanced kidney or liver disease
Comparison with Similar Peptides
| Property | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor targets | GIP + GLP-1 + Glucagon | GIP + GLP-1 | GLP-1 |
| Classification | Triagonist | Dual agonist | Monoagonist |
| Backbone | GIP-based | GIP-based | GLP-1-based |
| Administration | 1× weekly s.c. | 1× weekly s.c. | 1× weekly s.c. |
| Max. dose | 12 mg | 15 mg | 2.4 mg |
| Weight loss (max.) | −28.7% (Phase 3) | −22.5% (Phase 3) | −16.9% (Phase 3) |
| Liver fat reduction | Up to −86% | Reduction shown | Moderate reduction |
| Appetite suppression | Moderate | Strong | Very strong |
| Energy expenditure ↑ | Yes (via glucagon) | Low | No |
| Approval status | Phase 3 | Approved | Approved |
| Manufacturer | Eli Lilly | Eli Lilly | Novo Nordisk |
Important: Weight loss data come from different studies. A direct head-to-head comparison has not been conducted.
FAQ
What is retatrutide? Retatrutide (LY3437943) is an investigational synthetic peptide from Eli Lilly that, as the world's first triple hormone receptor agonist, simultaneously activates GIP, GLP-1 and glucagon receptors.
How does retatrutide work? Retatrutide activates three metabolic receptors simultaneously: The GIP receptor improves insulin sensitivity and lipid metabolism, the GLP-1 receptor reduces appetite and improves blood glucose control, and the glucagon receptor increases energy expenditure and fat burning.
Is retatrutide safe? Study data to date show a safety profile comparable to other incretin therapies. The most common side effects are gastrointestinal complaints. In the Phase 3 TRIUMPH-4 study, a new signal – dysesthesia – was observed.
How is retatrutide dosed? In clinical studies, dosing begins at 2 mg/week, is escalated every 4 weeks, and reaches a maintenance dose of 8–12 mg/week.
Retatrutide vs. semaglutide – what is the difference? Semaglutide is a GLP-1 monoagonist that works primarily through appetite suppression. Retatrutide additionally activates GIP and glucagon receptors, allowing it to not only reduce appetite but also increase energy expenditure and improve fat metabolism.
Is retatrutide approved? No. Retatrutide is in Phase 3 clinical trials. Approval is expected no earlier than 2027. As a research peptide, retatrutide is available exclusively for research purposes.
References
- Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022;400:1869–1881.
- Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514–526.
- Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. Lancet. 2023;402:529–544.
- Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30(7):2037–2048.
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab. 2022;34:1234–1247.
- Eli Lilly Press Release: TRIUMPH-4 Phase 3 Results. December 11, 2025.
- Pasqualotto E et al. Effects of once-weekly subcutaneous retatrutide. Metabolism Open. 2024;24:100321.
This article was written by the Jade Peptides Research Team and medically reviewed.
Reviewed by medical professionals